JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.

JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
复制标题

DOI:
10.1084/jem.20201268
复制
发表时间:
2021-02-01
期刊:
The Journal of experimental medicine
影响因子:
--
通讯作者:
de Thé H
de Thé H
中科院分区:
其他
文献类型:
--
作者:
Dagher T;Maslah N;Edmond V;Cassinat B;Vainchenker W;Giraudier S;Pasquier F;Verger E;Niwa-Kawakita M;Lallemand-Breitenbach V;Plo I;Kiladjian JJ;Villeval JL;de Thé H

文献摘要

参考文献

被引文献

相似文献

骨髓增生性肿瘤对α干扰素治疗部分敏感。达格尔等人。证明三氧化二砷通过靶向干扰素靶标和关键衰老基因 PML,显着增强干扰素从小鼠模型中消除患者祖细胞或疾病起始细胞的能力。干扰素 α (IFNα) 用于治疗 JAK2V617F 驱动的骨髓增生性肿瘤 (MPN),但很少能治愈该疾病。我们研究了 IFNα 的作用机制,重点关注 PML,这是一种干扰素靶点和关键衰老基因,三氧化二砷 (ATO) 的靶向作用可促进急性早幼粒细胞白血病的根除。 ATO 显着增强 IFNα 诱导的 JAK2V617F 患者或小鼠造血祖细胞的生长抑制,这需要 PML 并与衰老特征相关。在小鼠 MPN 模型中,将 ATO 与 IFNα 结合可增强和加速反应,通过靶向疾病起始细胞来根除大多数小鼠的 MPN。这些结果预测了 IFNα+ATO 组合对患者的有效临床疗效,并将 PML 确定为治疗的主要效应物,即使在具有完整 PML 基因的恶性肿瘤中也是如此。
Myeloproliferative neoplasms are partly sensitive to interferon α therapy. Dagher et al. demonstrate that arsenic trioxide sharply potentiates interferon’s ability to eliminate patients’ progenitors or disease-initiating cells from mouse models by targeting PML, an interferon target and key senescence gene. Interferon α (IFNα) is used to treat JAK2V617F-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by arsenic trioxide (ATO) drives eradication of acute promyelocytic leukemia. ATO sharply potentiated IFNα-induced growth suppression of JAK2V617F patient or mouse hematopoietic progenitors, which required PML and was associated with features of senescence. In a mouse MPN model, combining ATO with IFNα enhanced and accelerated responses, eradicating MPN in most mice by targeting disease-initiating cells. These results predict potent clinical efficacy of the IFNα+ATO combination in patients and identify PML as a major effector of therapy, even in malignancies with an intact PML gene.
PML:超越肿瘤抑制的调节和多面功能。
DOI: 10.1186/s13578-018-0204-8
发表时间: 2018
期刊: Cell & bioscience
影响因子: 7.5
作者:
Hsu KS;Kao HY
通讯作者: Kao HY
DOI: 10.1182/blood-2012-05-432989
发表时间: 2013-05-02
期刊: BLOOD
影响因子: 20.3
作者:
Mullally, Ann;Bruedigam, Claudia;Lane, Steven W.
通讯作者: Lane, Steven W.
DOI: 10.1016/j.clml.2014.06.014
发表时间: 2014-09-01
影响因子: 2.7
作者:
Pasquier, Florence;Cabagnols, Xenia;Vainchenker, Williai
通讯作者: Vainchenker, Williai
DOI: 10.1126/science.1189157
发表时间: 2010-11-26
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Giorgi C;Ito K;Lin HK;Santangelo C;Wieckowski MR;Lebiedzinska M;Bononi A;Bonora M;Duszynski J;Bernardi R;Rizzuto R;Tacchetti C;Pinton P;Pandolfi PP
通讯作者: Pandolfi PP
DOI: 10.1182/blood-2009-03-211821
发表时间: 2009-06-25
期刊: BLOOD
影响因子: 20.3
作者:
Kchour, Ghada;Tarhini, Mahdi;Bazarbachi, Ali
通讯作者: Bazarbachi, Ali